Tripos and Cara Announce Medicinal Chemistry Partnership
News Mar 23, 2006
Tripos, Inc. has announced that Tripos Discovery Research Ltd. has formed research collaboration with Cara Therapeutics. Cara is focused on developing therapeutics to treat medical conditions associated with pain and inflammation.
A team of computational and medicinal chemists at TDR will work in partnership with Cara's project team to support its drug discovery programs.
By combining Tripos' proprietary informatics tools with its expertise in medicinal chemistry, TDR's chemists will focus on the development of novel molecules for Cara's specific needs.
Based on Tripos' contribution, these molecules have the potential to progress into full clinical development more quickly than current industry norms.
"I am confident in Tripos' capabilities to accelerate discovery programs," said Dr. Derek Chalmers, CEO and president of Cara Therapeutics. "Tripos' domain expertise in this therapeutic area complements our own, and we look forward to a fruitful partnership."
"We are delighted that Cara has selected Tripos Discovery Research to support its efforts to discover new medicines in the area of neuropathic pain," said Dr. Mark Allen, senior vice president and managing director of TDR.
"The therapeutic options currently available to treat these debilitating conditions are very limited. This relationship, which leverages a component of our G-protein-coupled receptor LeadDiscovery™ library, underscores the high value attributed to our expertise and therapeutic medicinal chemistry capabilities."
Tuberculosis (TB), an ancient and notoriously difficult disease to treat, has killed millions through the course of human history; and the antibiotics that have been used to fight the disease in recent history are becoming less and less effective. In the face of this reality, researcher Prof. Dennis Wright has improved upon a new way to thwart the tricky pathogen, mycobacterium tuberculosis.READ MORE
Researchers have solved the structures of the cancer-promoting enzymes USP25 and USP28, and identified significant differences in their activities. This knowledge provides the molecular basis for the development of new and highly specific anti-cancer drugs, with a low risk of side-effects.READ MORE